The Claim
In obese, nondiabetic women, exenatide treatment leads to an average reduction of 1.68 cm in waist circumference over 16 weeks, suggesting a decrease in abdominal adiposity independent of lifestyle intervention.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
Taking a drug called exenatide for 16 weeks helps obese women who don’t have diabetes lose about 1.7 cm from their waist, even if they don’t change their diet or exercise.
See the scientific wording
Exenatide treatment reduces waist circumference by 1.68 cm on average over 16 weeks in obese, nondiabetic women, indicating a reduction in abdominal adiposity independent of lifestyle intervention.
What the research says
1 studyThe study looked at the same medicine (exenatide) in the same kind of people (obese women without diabetes) and found it reduced waist size, which supports the claim.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.